ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
On 06/29/20, ObsEva announced it will hold a conference call to discuss results from Phase 3 PRIMROSE 1 and PRIMROSE 2 clinical trials evaluating their drug Linzagolix in women with Uterine Fibroids.
I personally think the conference call will be Bullish because on 07/01/20, ObsEva and Yuyuan BioScience Technology announced submission of the PRE-IND Dossier for Nolasiban with Chinese NMPA.
This company has a few things going on that could be a catalyst for the stock moving into July 6, next week.
Daily Chart is Bullish
50-Day MA just crossed up above the 200-Day MA - I believe this cross just happened today on above average volume.
MACD is turning up, Bullish
RSI is Bullish
Stochastic is Bullish
The Cloud indicators are all Bullish as seen below.
8-May-20
3.36 Bullish Kumo Breakout
5-May-20
2.95 Bullish Senkou Span Cross
4-May-20
2.41 Bullish Kijun Sen Cross
29-Apr-20
2.55 Bullish Tenkan/Kijun Cross
20-Apr-20
2.10 Bullish Chikou Span Cross
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
On 06/29/20, ObsEva announced it will hold a conference call to discuss results from Phase 3 PRIMROSE 1 and PRIMROSE 2 clinical trials evaluating their drug Linzagolix in women with Uterine Fibroids.
I personally think the conference call will be Bullish because on 07/01/20, ObsEva and Yuyuan BioScience Technology announced submission of the PRE-IND Dossier for Nolasiban with Chinese NMPA.
This company has a few things going on that could be a catalyst for the stock moving into July 6, next week.
Daily Chart is Bullish
50-Day MA just crossed up above the 200-Day MA - I believe this cross just happened today on above average volume.
MACD is turning up, Bullish
RSI is Bullish
Stochastic is Bullish
The Cloud indicators are all Bullish as seen below.
8-May-20
3.36 Bullish Kumo Breakout
5-May-20
2.95 Bullish Senkou Span Cross
4-May-20
2.41 Bullish Kijun Sen Cross
29-Apr-20
2.55 Bullish Tenkan/Kijun Cross
20-Apr-20
2.10 Bullish Chikou Span Cross
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Comment:
Not sure why the stock is down. Positive clinical trial data this morning. Company is submitting data to the FDA. The stock should have spiked on the news.